Tuning Into Radiotherapeutics: Considerations for Oncology Trials

9

February

  • 3PM London / 10AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

Radiopharmaceutical therapy is emerging as a safe and effective targeted approach to treating many types of cancer. Clinical trials for these therapies are complex requiring a multi-disciplinary approach and careful coordination to produce meaningful and conclusive results.

In this webinar, we will look at the history and future trajectory of radiopharmaceuticals, describe their potential advantages, examine challenges specific to the development of these therapies, and identify key considerations for clinical trials, from meeting regulatory demands to recruiting patients. Topics will include:

  • How radiopharmaceuticals have evolved since 1903, when Alexander Graham Bell introduced the idea of placing radium-containing sources in or near tumors
  • What’s ahead: advances in production and availability of new isotopes, new imaging technologies, discovery of new targets, and more
  • Regulatory requirements, which differ considerably depending on geography

Patient recruitment: overcoming misconceptions about exposure to radioactivity and management of travel for site visits and study assessments.

Key Learning Objectives:

  • How radiopharmaceuticals have evolved
  • Advances in radiopharmaceuticals
  • Regulatory requirements
  • Patient Recruitment

Speakers

Select a speaker to learn more

Back
Ashley Herrick, Ph.D.
Executive Director, Oncology Program Strategy, Premier Research

Dr. Ashley Herrick provides strategic planning, coordination, knowledge, and expertise for oncology projects. She has more than 14 years of experience in oncology clinical trial oversight and drug development. She has experience with all phases of clinical trials but has a keen interest and deep knowledge of early phase and first-in-man studies. She has led numerous global clinical trials and has experience with strategic management, study oversight, study start-up, efficient enrollment, and study close-out/CSR development.

Prior to joining Premier Research, Dr. Herrick was Director of Operational Strategy Management for a mid-sized CRO overseeing the strategic planning for studies. She also supported their Oncology Site Network and was responsible for oversight of a biomarker driven patient matching group. She has also served as Project Director, Project Manager, and CRA throughout her years working in the CRO industry and has devoted her entire career to Oncology research. Prior to joining the CRO industry, she worked as a Program Manager for largest Phase I clinical trial unit in the country at MD Anderson Cancer Center, where she was responsible for oversight of more than 50 industry sponsored and investigator led Phase I clinical trials.

Dr. Herrick holds a doctorate degree in molecular and cellular biology with a focus on hematologic malignancies from Baylor College of Medicine. She is CCRP certified and is a member of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). She is an active volunteer with the Leukemia and Lymphoma Society (LLS).

Next speaker
Back
Rupa Doshi, Ph.D.
Vice President, Oncology Strategy, Premier Research

With more than 23 years in the industry, Dr. Doshi is an experienced professional with demonstrated leadership skills in clinical operations, global project/program management, customer management and strategy development. Her experience spans the clinical development spectrum from pre-IND to NDA and she has also led global teams in the execution of full-service complex clinical trials across all phases.

Next speaker

Enquiry